Pharming Group Appoints Kenneth Lynard as Chief Financial Officer to Drive Growth Strategy
Pharming Group Names Kenneth Lynard as Chief Financial Officer
Leiden, The Netherlands, September 2, 2025 — Pharming Group N.V. (Euronext: PHARM; Nasdaq: PHAR) has announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. This strategic leadership change comes on the heels of strong first-half 2025 financial results, aligning with Pharming’s commitment to strengthening its financial leadership and advancing its long-term growth strategy.
Kenneth Lynard’s Background and Expertise
Mr. Lynard brings over 20 years of global finance leadership in the life sciences sector, with a notable track record of leading financial and operational transformations at multinational organizations. His experience spans established industry leaders as well as dynamic, growth-focused companies in both the US and Europe. Prior to joining Pharming, Lynard held CFO roles at Schoeller Allibert and Zentiva, and previously served as CFO at Affidea. He was also Senior Vice President and CFO, Global Commercial Operations, R&D and Manufacturing at Gilead Sciences, overseeing capital allocation and pipeline funding strategies that contributed to significant business growth. Earlier in his career, He held senior finance positions at Medtronic, Coloplast, and Superfos, and started his career as a public accountant with Arthur Andersen. Lynard holds a Master of Science in Business Economics and Auditing from Copenhagen Business School and an Executive MBA from IMD in Lausanne, Switzerland.
Strengthening Pharming’s Growth and Investment Portfolio
Fabrice Chouraqui, CEO of Pharming Group, highlighted Lynard’s broad finance and operational expertise as a significant asset: “We are delighted to welcome Kenneth to Pharming at a critical time in our growth. His experience in managing investment risk and value creation within leading firms will be vital as we deliver on our growth strategy and enhance our investment portfolio.”
Lynard commented on his new role, stating, “I’m excited to join Pharming at such a pivotal stage. The foundation for long-term success is strong, supported by robust operational efficiency and a purpose-driven commitment to patients living with rare diseases. I look forward to supporting sustainable value creation through careful risk and investment management.”
About Pharming Group N.V.
Pharming Group N.V. is a global biopharmaceutical company based in Leiden, the Netherlands, dedicated to transforming the lives of patients with rare and life-threatening diseases. The company commercializes and develops a diverse investment portfolio of innovative treatments, serving patients in over 30 markets worldwide.
This content is for informational purposes only and does not constitute financial advice.
